Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovac Files to Start Trial of Bacterial Vaccine

publication date: Jan 31, 2011
Sinovac Biotech submitted a request to the SFDA to conduct a clinical trial of its newly developed 23-valent and 24-valent pneumococcal polysaccharides vaccines (PPV). The vaccines are designed to protect against pneumonia, meningitis and febrile bacteremia along with sinusitis and bronchitis. The target populations are children over the age of two and adults, especially those older than 65 and those with long-term health problems. More details....

Stock Symbol: (NSDQ: SVA)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital